2 active not recruiting, 2 recruiting. 4 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 2, Recruiting 2 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Double-Expressor Lymphoma: new trials by email Literature Review of Double-Expressor Lymphoma trials Research Report on Double-Expressor Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene Biopsy Procedure, Biospecimen Collection, Computed Tomography - Burkitt Lymphoma, Double-Expressor Lymphoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 50 | 2027-01-11 | 2026-10-14 |
| RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL RLC-CRCHOP - Double-expressor Lymphoma | Phase 2 | Recruiting | Zhejiang Cancer Hospital | 44 | 2024-11-06 | 2024-11-18 |
| Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma Cyclophosphamide, Doxorubicin, Etoposide - Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | Phase 2 | Active not recruiting | University of California, Davis | 24 | 2023-05-24 | 2026-09-28 |
| Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 363 | 2019-10-22 | 2026-10-22 |
Burkitt Lymphoma (1) · Lymphoma, Large B-Cell, Diffuse (1)
Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoma, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · DNA Virus Infections (1) · Epstein-Barr Virus Infections (1) · Herpesviridae Infections (1) · Infections (1) · Tumor Virus Infections (1)
Biopsy (2) · CT-P10 (2) · Cyclophosphamide (2) · Doxorubicin (2) · Etoposide (2) · Magnetic Resonance Spectroscopy (2) · Prednisone (2) · Rituximab (2) · Specimen Handling (2) · Spinal Puncture (2) · Vincristine (2) · deltacortene (2) · prednylidene (2) · CX 5461 (1) · loncastuximab tesirine (1)
National Cancer Institute (NCI) (2) · University of California, Davis (1) · Zhejiang Cancer Hospital (1)
United States (3) · China (1)
Jeremy S Abramson (1) · Joseph M Tuscano (1) · Sami Ibrahimi (1)
P30CA093373 (1), U10CA180821 (1), UM1CA186689 (1)